Novartis posts 6% rise in thirdquarter operating income on new drug sales ReutersOctober 27, 2025 at 11:52 PM 0 FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020.
- - Novartis posts 6% rise in third-quarter operating income on new drug sales
ReutersOctober 27, 2025 at 11:52 PM
0
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File Photo
FRANKFURT (Reuters) -Swiss drugmaker Novartis, on a deal-making spree this year, reported a 6% gain in operating income as growth of its new drugs outpaced stagnant revenue from established heart drug Entresto.
Third-quarter operating income, adjusted for special items, rose to $5.46 billion, it said on Tuesday, slightly above consensus numbers cited by analysts of $5.4 billion.
Novartis has made a push for acquisitions and licensing deals worth up to $30 billion this year, including a $12 billion deal for U.S. biotech firm Avidity, to bolster its drug pipeline and make up for a sales decline from established treatments losing patent protection.
The company, which has raised its outlook twice this year, confirmed its 2025 forecast and said it expected sales to grow by a "high single-digit" percentage and adjusted operating income to grow by a "low-teens" percentage.
Quarterly sales of its top-selling heart drug Entresto, which lost patent protection this year, was at $1.88 billion for the third quarter. Launched a decade ago, Entresto was Novartis' top-selling medicine in 2024 with sales of $7.82 billion worldwide.
Analysts were expecting sales of $1.77 billion for the quarter, according to LSEG data.
In July, a U.S. federal judge rejected Novartis' request to stop MSN Pharmaceuticals from selling a generic version of Entresto. Analysts project sales of the drug will cross $8 billion this year but will drop to about $6 billion in 2026, according to LSEG data.
Sales of the firm's psoriasis drug Cosentyx, which faces competition in the treatment of certain types of psoriasis and arthritis from UCB's Bimzelx, were mostly flat on-year at about $1.7 billion.
Sales of breast cancer drug Kisqali, launched last year, came in at $1.33 billion.
(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London; Editing by Friederike Heine and Janane Venkatraman)
Source: "AOL Money"
Source: ALPHA MAG
Full Article on Source: ALPHA MAG
October 28, 2025 at 09:18AM